This is a pre-revenue biotech with a cash runway of roughly 12-18 months at current burn rates. The strategic review process is a binary catalyst; the absence of any disclosed outcome or new financing means the stock remains dependent on partnership/licensing deals or a sale. Traders should watch for developments in the strategic review and any clinical milestones from the PeriNess study.
Price Chart
Executive Summary
Xenetic Biosciences reported Q2 2026 financial results, with royalty revenue increasing 12% YoY to ~$0.7M, but the net loss widened to ~$0.9M from ~$0.7M due to a 64% jump in G&A expenses tied to its strategic review process. The company highlighted positive preclinical DNase data at ASCO and an approved investigator-initiated CAR T study, while cash reserves fell to $6.5M from $7.9M at year-end 2025.
Key Financial Metrics
Key Facts
- Royalty revenue for Q2 2026 increased ~12% to ~$0.7M from ~$0.6M in Q2 2025.
- Research and development expenses decreased ~16% to ~$0.6M from ~$0.7M.
- General and administrative expenses increased ~64% to ~$1.1M from ~$0.7M due to higher legal costs from the strategic review.
- Net loss for Q2 2026 was ~$0.9M, compared to ~$0.7M in Q2 2025.
- Cash and cash equivalents totaled ~$6.5M as of June 30, 2026, down from ~$7.9M at December 31, 2025.
- Positive preclinical DNase I data was presented at the 2026 ASCO Annual Meeting.
- PeriNess Ltd. received regulatory approval for an investigator-initiated study of DNase I plus CAR T in large B-cell lymphoma.
- The company received approximately $1.5M in royalty revenue during the first six months of 2026.
Financial Impact
Net loss widened to $0.9M from $0.7M; cash burn of $1.4M in six months; royalty revenue of $0.7M for Q2.
Risk Factors
- Cash is declining; raised legal costs suggest a strategic review may not have a near-term resolution.
- No disclosed clinical trial enrollment or regulatory filing for the DNase platform.
- Royalty revenue (Takeda sublicense) is modest and not sufficient to cover operating expenses.
- Micro-cap with low liquidity and high sensitivity to news flow (0% analyst bullish consensus).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-006077 |
| Document: xenetic_ex9901.htm | 0001683168-26-006077 |
| Document: 0001683168-26-006077-index-headers.html | 0001683168-26-006077 |
| Document: 0001683168-26-006077-index.html | 0001683168-26-006077 |
| Document: 0001683168-26-006077.txt | 0001683168-26-006077 |
| 8-K Data (Synthetic) | 0001683168-26-006077 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | 8-K | $2.47 $1.93 | ▼ −21.86% | ▼ −21.44% | $1.85 (−25.10%) |
Sep 18, 2026 5w ago | SC 13G | $2.77 $1.99 | ▼ −28.16% | ▼ −28.36% | $1.85 (−33.21%) |
Sep 16, 2026 5w ago | 8-K | $2.19 $2.10 | ▼ −4.11% | ▼ −7.29% | $1.85 (−15.53%) |
Aug 7, 2026 11w ago | 8-K | $3.17 $4.67 | ▲ +47.32% | ▲ +47.72% | $1.85 (−41.64%) |
May 13, 2026 23w ago | 8-K | $3.18 $3.00 | ▼ −5.66% | ▼ −5.05% | $1.85 (−41.82%) |
Apr 24, 2026 26w ago | 10-K/A | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.85 (−38.94%) |
Apr 24, 2026 26w ago | 8-K | $3.03 $3.07 | ▲ +1.18% | ▼ −3.77% | $1.85 (−38.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers